Neurocrine Biosciences (NBIX) Stock: Buy, Sell, or Hold?
NBIX - Neurocrine Biosciences Inc
$156.22
-0.35 (-0.22%)
▼
5d:
-1.35%
30d:
-0.17%
90d:
-3.99%
BUY
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 27, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 8, 2026 at $156.19 · last confirmed Sep 9, 2026
Strength: 4.8/10
Get Alerted When NBIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NBIX shows positive signals but monitor for confirmation. Market pricing in 1.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NBIX shows positive signals but monitor for confirmation. Market pricing in 1.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$271.45
Based on 10.7% avg growth
INTRINSIC VALUE TODAY
$168.55
7.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NBIX is currently trading at $156.22, which is considered fair relative to its 30-day fair value range of $152.91 to $161.16. The stock's valuation (Forward PE: 13.1) is in line with its historical norms (13.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This pessimistic expectation contrasts with the company's recent 31.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NBIX is in a uptrend. The price is currently testing key support at $151.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NBIX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $211.72 (+35.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NBIX is in a uptrend. The price is currently testing key support at $151.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NBIX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $211.72 (+35.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$152.91 -
$161.16
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.5% below Wall St target ($211.72)
- BULLISH: Bottoming setup score 65/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$152.91 -
$161.16
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$151.77
Resistance Level
$160.43
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.05
Wall Street Target
$211.72
(+35.5%)
Revenue Growth (YoY)
39.5%
Earnings Growth (YoY)
31.1%
Profit Margin
20.9%
Valuation Discount vs History
-1.5% cheaper
PE vs Historical
13.1 vs 13.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.5%
(market-implied from PE analysis)
1-Year Target
$153.88
(-2%)
2-Year Target
$151.57
(-3%)
3-Year Target
$149.30
(-4%)
3-Yr Target (if PE normalizes)
(PE: 13→14)
$156.77
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 17.4%)
$391.05
(+150%)
Base:
(SPY PE: 13.0, Growth: 17.4%)
$252.95
(+62%)
Bear:
(PE: 11.1, Growth: 17.4%)
$215.01
(+38%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 22.69 | Current EPS (TTM): $6.90
Bull Case
$298.87
(+91%)
Analyst growth 73.5%, PE expands to 25.0
Base Case
$271.70
(+74%)
Market implied 73.5%, PE stable at 22.7
Bear Case
$106.47
(-32%)
Severe decline -20.0%, PE contracts to 19.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.0 to 13.7
Stabilization Target:
$164.04
(+5.0%)
PE Expansion Potential:
+5.0%
Share & Embed Analysis
Last updated: September 13, 2026 7:27 PM ET
Data refreshes hourly during market hours. Next update: 8:27 PM
Data refreshes hourly during market hours. Next update: 8:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
Advanced NBIX Option Strategies
Professional options setups generated by AI based on today's NBIX price and gamma walls.
